Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) Treatment Regimen for Multiple Myeloma
For transplant-eligible newly diagnosed multiple myeloma, the D-VRd regimen consists of daratumumab 16 mg/kg IV weekly during induction (weeks 1-8), then every 2 weeks during consolidation post-ASCT, followed by daratumumab plus lenalidomide maintenance until progression. 1
Induction Phase (Pre-ASCT)
Weeks 1-8 (4-week cycles):
- Daratumumab: 16 mg/kg IV weekly (total 8 doses)
- Bortezomib: 1.3 mg/kg subcutaneously on days 1,4,8,11 of each 21-day cycle
- Lenalidomide: 25 mg orally days 1-14 of each 21-day cycle
- Dexamethasone: 40 mg orally on days 1,2,8,9,15,16 of each 21-day cycle (20 mg on day of and day after bortezomib) 2, 3
Weeks 9-16:
- Daratumumab: Every 2 weeks (total 4 doses)
- Continue VRd as above 1
This induction phase delivers 4 cycles before proceeding to stem cell harvest and ASCT.
Post-ASCT Consolidation Phase
Weeks 1-8 after ASCT:
- Daratumumab: Every 2 weeks (total 4 doses)
- VRd: Continue as per induction dosing 1
Typically 2 consolidation cycles are administered. 4
Maintenance Phase
Week 25 onwards until disease progression:
- Daratumumab: 16 mg/kg IV every 4 weeks
- Lenalidomide: 10-15 mg orally days 1-21 of each 28-day cycle (dose adjusted based on tolerability) 1
Critical modification: Patients achieving sustained MRD negativity for ≥12 months may receive daratumumab-lenalidomide maintenance for up to 2 years, then transition to lenalidomide alone. All other patients continue daratumumab-lenalidomide until progression. 5, 6
Evidence Supporting This Regimen
The PERSEUS trial demonstrated that D-VRd followed by daratumumab-lenalidomide maintenance achieved superior outcomes compared to VRd alone in transplant-eligible patients 6:
- 48-month PFS: 84.3% vs 67.7% (HR 0.42, P<0.001)
- Complete response rate: 87.9% vs 70.1%
- MRD negativity: 75.2% vs 47.5%
The GRIFFIN trial confirmed these benefits with stringent CR rates of 62.6% vs 45.4% and MRD negativity of 51.0% vs 20.4% at 22 months. 4
Essential Supportive Care
- Herpes zoster prophylaxis: Required for all patients receiving bortezomib 7
- Thromboprophylaxis: Aspirin 81-325 mg daily for standard-risk patients; therapeutic anticoagulation (LMWH, warfarin, or DOACs) for high-risk patients receiving lenalidomide 2, 7
- Pneumocystis prophylaxis: Recommended for all patients on dexamethasone 7
- Levofloxacin: Consider during first 2 cycles to reduce infection risk 7
Infusion-Related Reaction Management
Pre-medications before daratumumab:
- Montelukast 10 mg orally or equivalent antihistamine
- Acetaminophen 650-1000 mg orally
- Diphenhydramine 25-50 mg IV or oral
- Corticosteroid (already included as dexamethasone in regimen) 1
Post-infusion: Corticosteroid (oral methylprednisolone 20 mg or equivalent) on days 1-2 after each daratumumab infusion 1
Common Pitfalls and Management
Stem cell mobilization: Plerixafor use is more common with D-VRd (required in approximately 30% of patients) compared to VRd alone, though median CD34+ cell yield remains adequate (8.2 × 10⁶/kg). 4 Plan for potential plerixafor need during mobilization.
Hematologic toxicity: Grade 3-4 neutropenia occurs in 62% (vs 51% with VRd) and thrombocytopenia in 29% (vs 17% with VRd). 6 Monitor CBC weekly during induction and adjust lenalidomide/bortezomib doses per standard guidelines.
Infection risk: While overall infection rates are higher with D-VRd, grade 3-4 infection rates are similar to VRd (approximately 15-20%). 4 The prophylactic measures above are critical.
Peripheral neuropathy: Subcutaneous bortezomib administration (preferred route) reduces neuropathy risk compared to IV. 2, 8 If grade 2 or higher neuropathy develops, reduce bortezomib dose or switch to weekly dosing.
For Transplant-Ineligible Patients
The CEPHEUS trial established that 8 cycles of D-VRd followed by daratumumab-lenalidomide maintenance until progression is superior to VRd in transplant-ineligible patients, with MRD negativity of 60.9% vs 39.4% (P<0.0001). 9 Use the same dosing as above but continue for 8 cycles total before transitioning to maintenance.
Alternative for transplant-ineligible patients: DRd (daratumumab-lenalidomide-dexamethasone without bortezomib) is appropriate for patients with pre-existing neuropathy or bortezomib intolerance. 7, 10